Yuting Lu

Yuting Lu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMing Han
Ming Han
YLYuting Lu
Yuting Lu
YTYunhua Tao
Yunhua Tao
XZXinwen Zhang
Xinwen Zhang
CDChengqiu Dai
Chengqiu Dai
JLJingya Li
Jingya Li
Diabetes, which is mainly characterized by increased apoptosis and dysfunction of beta (β) cells, is a metabolic disease caused by impairment of pancreatic islet function. Previous studies have demonstrated that death-associated protein kinase-related apoptosis-inducing kinase-2 (Drak2) is involved in regulating β cell survival. Since natural products have multiple targets and often are multifunctional, making them promising compounds for the treatment of diabetes, we identified Drak2 inhibitors from a natural product library. Among the identified products, luteolin, a flavonoid, was found to be the most effective compound. In vitro, luteolin effectively alleviated palmitate (PA)-induced apoptosis of β cells and PA-induced impairment of primary islet function. In vivo, luteolin showed a tendency to lower blood glucose levels. It also alleviated STZ-induced apoptosis of β cells and metabolic disruption in mice. This function of luteolin partially relied on Drak2 inhibition. Furthermore, luteolin was also found to effectively relieve oxidative stress and promote autophagy in β cells, possibly improving β cell function and slowing the progression of diabetes. In conclusion, our findings show the promising effect of Drak2 inhibitors in relieving diabetes and offer a potential therapeutic target for the protection of β cells. We also reveal some of the underlying mechanisms of luteolin’s cytoprotective function.

7 February 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
YLYuting Lu
Yuting Lu
JXJunyu Xu
Junyu Xu
YLYufeng Li
Yufeng Li
RWRuoran Wang
Ruoran Wang
CDChengqiu Dai
Chengqiu Dai
JLJingya Li
Jingya Li
Impeded autophagy can impair pancreatic β cell function by causing apoptosis, of which DAP-related apoptosis-inducing kinase-2 (DRAK2) is a critical regulator. Here, we identified a marked up-regulation of DRAK2 in pancreatic tissue across humans, macaques, and mice with type 2 diabetes (T2D). Further studies in mice showed that conditional knockout (cKO) of DRAK2 in pancreatic β cells protected β cell function against high-fat diet feeding along with sustained autophagy and mitochondrial function. Phosphoproteome analysis in isolated mouse primary islets revealed that DRAK2 directly phosphorylated unc-51–like autophagy activating kinase 1 (ULK1) at Ser 56 , which was subsequently found to induce ULK1 ubiquitylation and suppress autophagy. ULK1-S56A mutation or pharmacological inhibition of DRAK2 preserved mitochondrial function and insulin secretion against lipotoxicity in mouse primary islets, Min6 cells, or INS-1E cells. In conclusion, these findings together indicate an indispensable role of the DRAK2-ULK1 axis in pancreatic β cells upon metabolic challenge, which offers a potential target to protect β cell function in T2D.

29 April 2026 in Journal of Diabetes
Verified
Journal Article
Open access
RLRuihan Li
Ruihan Li
BZBingqian Zhang
Bingqian Zhang
YZYuxin Zhang
Yuxin Zhang
YYYang Yang
Yang Yang
YLYuting Lu
Yuting Lu
JLJingya Li
Jingya Li
Mitochondrial homeostasis is essential for pancreatic β cell function, and its disruption underlies diabetes pathogenesis. Chronic hyperglycemia, lipotoxicity, and inflammation impair mitochondrial quality control (MQC), leading to β cell dysfunction, oxidative stress, and apoptosis. Mitochondria‐organelle interactions, particularly with the endoplasmic reticulum (ER), lysosomes, and Golgi apparatus, further exacerbate β cell dysfunction by disrupting calcium signaling and metabolic coordination. Emerging potential therapies, such as DRAK2 inhibitors and metabolic reprogramming agents, show promise in preserving MQC and β cell function. However, clinical validation is needed. This review highlights mitochondrial dysfunction as a central driver of diabetes and underscores the potential of mitochondrial‐targeted strategies for therapeutic intervention.

3 June 2026 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YSYuhang Shu
Yuhang Shu
BZBingqian Zhang
Bingqian Zhang
YZYuxin Zhang
Yuxin Zhang
XZXinwen Zhang
Xinwen Zhang
HXHonghong Xu
Honghong Xu
FYFan Yang
Fan Yang